HCHC +36% on JNJ’s acquisition of Benevir Biopharm (HCHC’s majority-owned subsidiary): https://finance.yahoo.com/news/hc2-announces-pansend-life-sciences-110306896.html [HCHC PR] https://www.prnewswire.com/news-releases/janssen-to-acquire-benevir-biopharm-to-advance-immunotherapy-regimens-300640969.html [JNJ PR] Benevir Biopharm has an oncolytic-virus platform.